Equal-WT
WhaleScore 2.0
?
LYNX1 CAPITAL MANAGEMENT LP
DORADO
Investment Advisor
Hedge Fund
Lynx1 Capital Management is based out of Dorado. Lynx1 Capital Management is a hedge fund with 5 clients and discretionary assets under management (AUM) of $310,306,368 (Form ADV from 2025-06-23). Their last reported 13F filing for Q3 2025 included $491,299,832 in managed 13F securities
and a top 10 holdings concentration of 98.81%. Lynx1 Capital Management's largest holding is Merus N.V with shares held of 1,534,141. Whalewisdom has at least 18 13F filings, 2 13D filings, and 42 13G filings
Investment Strategy
The Firm employs various investment strategies, including a long-only equity strategy focused on biotechnology for the Flagship Funds. This strategy aims to generate attractive, risk-adjusted returns over the long term by leveraging technological breakthroughs and advances in human health. The Firm relies on deep fundamental research, scientific expertise, and extensive experience to identify long investments for the Flagship Funds' portfolio, seeking attractive commercial rewards and managing technical risks. The Opportunity Fund invests its assets in one or more private companies.
Future client accounts are expected to pursue various strategies, some of which may be the same or similar to those of the Flagship Funds. The Firm may also invest opportunistically in securities or transactions that deviate from the core strategy of the Flagship Funds to respond to changing market conditions and new investment opportunities. The Funds' portfolio is expected to be concentrated in the biotechnology industry, exposing it to risks associated with this sector, including rapid technological advances and product obsolescence.
Owners
- LYNX1 CAPITAL MANAGEMENT GP LLC - GENERAL PARTNER
- NICHOLS, WESTON, AGNEW - CHIEF INVESTMENT OFFICER, LIMITED PARTNER
- PARTYKA ZAMORA, NATHALI, JOAQUINA - CHIEF COMPLIANCE OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-09-30
Top Buys (13F)
| Name | % Change |
|---|---|
| ADCT ADC Therapeutics SA | 1.08% |
| DNLI Denali Therapeutics | 0.77% |
| DTIL Precision BioScience | -0.09% |
| GHRS GH Research PLC | -2.53% |
| CGEM Cullinan Therapeutic | -2.61% |
2025-09-30
Top Sells (13F)
| Name | % Change |
|---|---|
| ALLO Allogene Therapeutic | 3.47% |
| PTGX Protagonist Therapeu | 2.24% |
| UPB Upstream Bio Inc | 0.7% |
| IBIO iBio Inc | 0.16% |
| NEUP Neuphoria Therapeuti | 0.09% |
2025-09-30
13F Holdings Summary
| Name | % of Portfolio |
|---|---|
| MRUS Merus N.V | 29.4% |
| STOK Stoke Therapeutics I | 22.37% |
| GHRS GH Research PLC | 21.23% |
| PTGX Protagonist Therapeu | 9.47% |
| CGEM Cullinan Therapeutic | 6.96% |
2025-09-30
13F Activity
| Market Value | $491m, Prior: $346m |
| Inflows (Outflows) as % of Total MV | +3.6591% |
| New Purchases | 2 stocks |
| Added To | 4 stocks |
| Sold out of | 3 stocks |
| Reduced holdings in | 4 stocks |
| Top 10 Holdings % | 98.81% |
| Turnover %[1] | 29.41% |
| Turnover Alt %[2] | -6.03% |
| Time Held Top 20 | 6.1429 quarters |
| Time Held Top 10 | 5.8 quarters |
| Time Held All | 6.14 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-09-30